Navigation Links
Cystic fibrosis and diabetes link explained
Date:6/2/2014

Many people with cystic fibrosis develop diabetes. The reasons for this have been largely unknown, but now researchers at Lund University in Sweden and Karolinska institutet have identified a molecular mechanism that contributes to the raised diabetes risk.

"The increased risk of diabetes has previously been explained by the fact that cystic fibrosis causes damage to the pancreas, where the blood-sugar regulating hormone insulin is produced. We are the first research group to show that the mutated gene that causes cystic fibrosis also plays an important role in the release of insulin. The risk of diabetes is not only explained by the destruction of the pancreas", said Anna Edlund, a doctoral student at Lund University Diabetes Centre.

Cystic fibrosis is the result of a genetic mutation in an ion channel that normally regulates salt transport in cells, primarily in the lungs and pancreas. The mutation leads to a wide variety of symptoms. Individuals with cystic fibrosis produce a lot of thick, viscous mucus. This makes their airways sensitive to infection, and repeated or chronic lung infections are common. The secretion of pancreatic juice from the pancreas to the intestine is hindered, which causes diarrhoea and poor weight gain.

Left untreated, cystic fibrosis is fatal, but with improved treatment of symptoms, survival has improved. Many people with cystic fibrosis now live beyond the age of 40.

"Cystic Fibrosis is a severe health condition and diabetes exacerbates an already problematic situation", said Malin Flodstrm-Tullberg, a researcher at the Centre for Infectious Medicine, Karolinska institutet.

Many people with cystic fibrosis have poor sugar metabolism. At the age of 30, around one in four people with cystic fibrosis also has diabetes that requires treatment with insulin. What the researchers have now shown is that the mutation in the cystic fibrosis gene inhibits the secretion of insulin into the blood, which means that the level is insufficient when the demands on the insulin increase, such as after a meal.

"Normally, insulin is released in two stages. The early stage is a rapid response to raised blood sugar and the later stage aims to restore blood sugar levels. In cystic fibrosis, the early stage of insulin release in particular is insufficient", said Anna Edlund, adding:

"Our results also correspond to clinical observations. Many patients with cystic fibrosis who do not have diabetes have normal blood sugar in a fasting state, but raised blood sugar after a meal."

The researchers have worked on insulin producing cells from mice and deceased donors. They have shown that the cystic fibrosis gene plays an important role in the complex chain of events that precedes the release of insulin.

When the cells were exposed to high glucose levels, they responded as expected by increasing insulin secretion, but when a preparation that specifically obstructs the ion channel expressed by the cystic fibrosis gene was added, the cells' ability to release insulin fell significantly.

"Despite being common among cystic fibrosis patients, surprisingly little is known about the mechanisms behind diabetes in this group of individuals. We need to know what causes the problem in order to develop preventive treatments that improve the cells' ability to secrete insulin. Our study provide a first piece of increased understanding how CFTR contribute to insulin secretion", said Lena Eliasson, Professor at Lund University Diabetes Centre.


'/>"/>

Contact: Lena Eliasson
lena.eliasson@med.lu.se
46-705-225-414
Lund University
Source:Eurekalert

Related medicine news :

1. Study evaluates use of inhaled saline for young children with cystic fibrosis
2. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
3. Cystic fibrosis patients of low SES are less likely to be accepted for lung transplant
4. Cystic kidney growth curbed
5. Impaired blood vessel function found in cystic fibrosis patients
6. Scientists identify new strategy to fight deadly infection in cystic fibrosis
7. Polycystic ovary syndrome puts glucose control in double jeopardy
8. Tiny RNA molecule may have role in polycystic ovary syndrome, insulin resistance
9. PCOS Diva Launches Spring Meal Plans For Women With Polycystic Ovarian Syndrome
10. New approaches in treating complicated childhood polycystic kidney disease
11. Fosamax Lawsuits Update: Rottenstein Law Group LLP Responds to Fosamax Cystic Fibrosis Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: